Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.
Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.
Iridex Corp (IRIX) insider purchase reported. Romeo R. Dizon, listed as Chief Financial Officer and reporting person, acquired a total of 1,500 shares on 08/18/2025 in two transactions: 460 shares at $1.19 and 1,040 shares at $1.1723. After these purchases he is shown as beneficially owning 40,745 shares.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported two open-market purchases of company common stock on 08/15/2025. He acquired 1,000 shares at $1.1799 per share and 500 shares at $1.15 per share, bringing his total reported beneficial ownership to 39,245 shares following the transactions. The Form 4 was signed on behalf of Mr. Dizon by an attorney-in-fact on 08/18/2025. No derivative transactions or other material changes were reported in this filing.
IRIDEX Corporation reported quarterly revenue of $13.6 million (up 7.4% year-over-year) and six-month revenue of $25.5 million (up 4.4%). Gross margin for the quarter was 34.5% versus 40.7% a year earlier, and six-month gross margin was 38.2%. The company recorded a net loss of $0.99 million for the quarter and $2.68 million for the six-month period. Cash and cash equivalents rose to $6.8 million and working capital was $13.2 million, supported by financing activity.
The company completed financings including issuance of 600,000 Series B preferred shares for $6.0 million and a $4.0 million convertible note; it also recognized a $1.3 million loss on extinguishment of a prior convertible note. Topcon remains a material related-party customer, representing ~32% of quarterly revenue and ~29% of accounts receivable. Inventories were $8.4 million and deferred revenue ended at $9.9 million.
IRIDEX Corporation disclosed a press release reporting its financial results for the second fiscal quarter ended June 28, 2025, and furnished that release as Exhibit 99.1 to this Form 8-K. The company specifies that the press release is furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act, meaning it is incorporated by reference only as expressly stated. The filing confirms the company’s common stock trades on the Nasdaq Capital Market under the symbol IRIX and is signed by Chief Executive Officer Patrick Mercer.
IRIDEX Corp (IRIX) Form 4: On 06/30/2025 President & CEO Patrick Mercer surrendered 4,243 common shares at $0.8819 under Transaction Code F. The shares were automatically withheld by the company to satisfy payroll-tax obligations tied to the net settlement of restricted stock units, so no open-market sale occurred.
After the withholding, Mercer still directly owns 415,857 IRIX shares, maintaining a significant equity stake. No derivative transactions were reported and there were no changes to his options or RSU schedule.
The disposition is valued at roughly $3.7 k, an amount that is immaterial relative to IRIDEX’s market capitalisation and Mercer's remaining holdings. As such, the filing carries limited market significance and is primarily an administrative compliance event.
This Form 4/A is an amendment to a previously filed Form 4 for Scott Shuda, a Director of Iridex Corp (IRIX), reporting a stock option grant on June 13, 2025. The original filing was made on June 17, 2025.
Key details of the transaction:
- Granted 53,000 stock options to purchase common stock
- Exercise price set at $0.94 per share
- Options expire on June 13, 2032
- Vesting occurs at earlier of: one-year anniversary of grant date or 2026 annual stockholder meeting
The options were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. The filing was signed by Nilo De Castro as attorney-in-fact for Scott Shuda on June 24, 2025.
This Form 4/A filing amends a previously filed Form 4 dated June 17, 2025, reporting insider trading activity for Beverly A. Huss, a Director of Iridex Corp (IRIX). The amendment discloses a stock option grant that occurred on June 13, 2025.
Key details of the transaction:
- Granted 53,000 stock options to purchase common stock
- Exercise price set at $0.94 per share
- Options expire on June 13, 2032
- Vesting occurs at earlier of one-year anniversary or 2026 annual stockholder meeting
The stock options were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. The filing was signed by Nilo De Castro as attorney-in-fact for Beverly Huss on June 24, 2025.
Iridex Corp director William M. Moore received two stock option grants on June 13, 2025, as reported in this Form 4 filing:
- First grant: 53,000 stock options with exercise price of $0.94, vesting fully on either the one-year anniversary or 2026 annual meeting
- Second grant: 15,000 stock options with exercise price of $0.94, vesting monthly over four years starting July 13, 2025
Both options were granted under the company's 2008 Equity Incentive Plan and expire on June 13, 2032. The grants are exempt under Rule 16b-3. This compensation structure aligns the director's interests with shareholders through both short-term and long-term vesting schedules. The low exercise price suggests the stock may be trading near historical lows.
Iridex Corp CFO Romeo R. Dizon filed an amended Form 4 reporting two significant equity transactions on June 13, 2025:
- Acquired 22,500 Restricted Stock Units (RSUs) at $0.94 per share, with vesting over three years starting June 13, 2026 (one-third annually)
- Received stock options to purchase 75,000 shares of common stock at an exercise price of $0.94, vesting over three years and expiring June 13, 2032
Following these transactions, Dizon directly owns 37,745 shares and 75,000 stock options. This amended filing corrects a previous Form 4 filed on June 17, 2025. The equity awards were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. These grants appear to be part of executive compensation arrangements, demonstrating long-term alignment with shareholder interests through multi-year vesting schedules.